The deal includes key technology, several intellectual property assets and cell lines, and staff.
Uncommon, which is based in Cambridge, is switching its focus away from cultivated meat and towards therapeutics following the sale.
Meanwhile, through the integration of Uncommon Bio’s non-GMO mRNA reprogramming and saRNA differentiation technologies, Meatable now operates a “true multi-platform cultivated meat technology offering”.
Meatable hopes that the deal will equip the company to accelerate time to market, navigate regulatory pathways worldwide, and adapt to diverse consumer preferences.
“I’m incredibly proud of what we’ve built at Uncommon Bio, a legacy of innovation and bold thinking in cultivated meat,” said Benjamina Bollag, CEO of Uncommon.
“After deciding to focus on therapeutics, we wanted to find the best home for our technology and it’s exciting to see Meatable carry our work forward and apply it at scale. I look forward to continuing our collaboration and watch their continued success and global impact in the years ahead.”
Jeff Tripician, CEO of Meatable, added: “This acquisition is more than a strategic step – it sets a new standard for cultivated meat production. By combining two highly complementary platforms, Meatable is now equipped to reliably deliver high-quality cultivated meat at a global scale.
This enables us to support the meat industry with a stable, secure, and future-proof supply of species like pork, beef, lamb, and poultry, ensuring business continuity and resilience in the face of increasingly uncertain times.”
The addition of Uncommon Bio’s technology accelerates product development for chicken and lamb, while its non-GMO status and regulatory ready dossier will support faster regulatory approval in multiple regions.
The acquisition also strengthens Meatable’s intellectual property portfolio with additional patents and proprietary assets, further consolidating its status as a technological leader in cellular agriculture.
“The value of the IP is strengthened by the calibre of investors who have supported Uncommon’s mission from the start,” noted Aris de Rijke, chief technology officer at Meatable.
“We’re proud to carry forward technology that has earned the trust of such respected backers, like Apollo Projects and Lower Carbon Capital, further fuelling our path toward success at scale.”
Meatable hosted the first-ever legally approved cultivated meat tasting in the EU last year, inviting a range of guests to sample its cultivated pork sausages.
